Imaging tumour angiogenesis

Cancer Imaging

Volumn 5, Issue 1, 2005, Pages 131-138

  Jeswani, Tony ^a   Padhani, Anwar R ^b  

^a ROYAL FREE HOSPITAL   (United Kingdom)

^b MOUNT VERNON HOSPITAL   (United Kingdom)

Author keywords

Angiogenesis; Imaging; Neovascularisation

Indexed keywords

COMPUTER ASSISTED TOMOGRAPHY; DIAGNOSTIC IMAGING; HUMAN; NEOPLASM; NEOVASCULARIZATION (PATHOLOGY); NUCLEAR MAGNETIC RESONANCE IMAGING; PATHOLOGY; REVIEW; VASCULARIZATION;

DIAGNOSTIC IMAGING; HUMANS; MAGNETIC RESONANCE IMAGING; NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC; TOMOGRAPHY, X-RAY COMPUTED;

EID: 33645229867     PISSN: None     EISSN: 14707330     Source Type: Journal    
DOI: 10.1102/1470-7330.2005.0106     Document Type: Article

References (63)

1. Knopp MV, Giesel FL, Marcos H, von Tengg-Kobligk H, Choyke P. Dynamic contrast-enhanced magnetic resonance imaging in oncology. Top Magn Reson Imaging 2001; 12: 301-8.
2. Padhani AR, Dzik-Jurasz A. Perfusion MR imaging of extracranial tumor angiogenesis. Top Magn Reson Imaging 2004; 15: 41-57.
3. Folkman J. Angiogenesis in cancer, vascular, rheumatoid and other disease. Nat Med 1995; 1: 27-31.
4. Gray LH, Conger AD, Ebert M, Hornsey S, Scott OC. The concentration of oxygen dissolved in tissues at the time of irradiation as a factor on radiotherapy. Br J Radiol 1953; 26: 638-48.
5. Kaban K, Herbst RS. Angiogenesis as a target for cancer therapy. Hematol Oncol Clin North Am 2002; 16: 1125-71.
6. Hahnfeldt P, Panigrahy D, Folkman J, Hlatky L. Tumor development under angiogenic signaling: a dynamical theory of tumor growth, treatment response, and postvascular dormancy. Cancer Res 1999; 59: 4770-5.
7. Folkman J. New perspectives in clinical oncology from angiogenesis research. Eur J Cancer 1996; 32A: 2534-9.
8. Dewhirst MW. Angiogenesis and blood flow in solid tumors. In: Drug Resistance in Oncology, Teicher B, ed. New York: Marcel Dekker, 1993: 3-24.
9. Heldin CH, Rubin K, Pietras K, Ostman A. High interstitial fluid pressure - an obstacle in cancer therapy. Nat Rev Cancer 2004; 4: 806-13.
10. Gilles R, Zafrani B, Guinebretiere JM et al. Ductal carcinoma in situ: MR imaging-histopathologic correlation. Radiology 1995; 196: 415-9.
11. Linderholm B, Tavelin B, Grankvist K, Henriksson R. Vascular endothelial growth factor is of high prognostic value in nodenegative breast carcinoma. J Clin Oncol 1998; 16: 3121-8.
12. Weidner N. Tumoural vascularity as a prognostic factor in cancer patients: the evidence continues to grow. J Pathol 1998; 184: 119-22.
13. Blomley MJ, Coulden R, Bufkin C, Lipton MJ, Dawson P. Contrast bolus dynamic computed tomography for the measurement of solid organ perfusion. Invest Radiol 1993; 28 (Suppl 5): S72-7 (discussion S78).
14. Miles KA, Leggett DA, Kelley BB, Hayball MP, Sinnatamby R, Bunce I. In vivo assessment of neovascularization of liver metastases using perfusion CT. Br J Radiol 1998; 71: 276-81.
15. Harvey C, Dooher A, Morgan J, Blomley M, Dawson P. Imaging of tumour therapy responses by dynamic CT. Eur J Radiol 1999; 30: 221-6.
16. Miles KA. Functional computed tomography in oncology. Eur J Cancer 2002; 38: 2079-84.
17. Dawson P. Contrast agents as tracers. In: Functional Computed Tomography, Miles KA, Dawson P, Hayball MP, eds. Oxford, UK: Isis Medical Media, 1997: 29-45.
18. Ferrara KW, Merritt CR, Burns PN, Foster FS, Mattrey RF, Wickline SA. Evaluation of tumor angiogenesis with US: imaging, Doppler, and contrast agents. Acad Radiol 2000; 7: 824-39.
19. Cheng WF, Lee CN, Chu JS et al. Vascularity index as a novel parameter for the in vivo assessment of angiogenesis in patients with cervical carcinoma. Cancer 1999; 85: 651-7.
20. Correas JM, Bridal L, Lesavre A, Mejean A, Claudon M, Helenon O. Ultrasound contrast agents: properties, principles of action, tolerance, and artifacts. Eur Radiol 2001; 11: 1316-28.
21. Jakobsen JA. Ultrasound contrast agents: clinical applications. Eur Radiol 2001; 11: 1329-37.
22. Laking GR, Price PM. Positron emission tomographic imaging of angiogenesis and vascular function. Br J Radiol 2003; 76 (Spec No 1): S50-9.
23. Barbier EL, Lamalle L, Decorps M. Methodology of brain perfusion imaging. J Magn Reson Imaging 2001; 13: 496-520.
24. Sorensen AG, Tievsky AL, Ostergaard L, Weisskoff RM, Rosen BR. Contrast agents in functional MR imaging. J Magn Reson Imaging 1997; 7: 47-55.
25. Simonsen CZ, Ostergaard L, Smith DF, Vestergaard-Poulsen P, Gyldensted C. Comparison of gradient- and spin-echo imaging: CBF, CBV, and MTT measurements by bolus tracking. J Magn Reson Imaging 2000; 12: 411-6.
26. Dennie J, Mandeville JB, Boxerman JL, Packard SD, Rosen BR, Weisskoff RM. NMR imaging of changes in vascular morphology due to tumor angiogenesis. Magn Reson Med 1998; 40: 793-9.
27. Bruening R, Berchtenbreiter C, Holzknecht N et al. Effects of three different doses of a bolus injection of gadodiamide: assessment of regional cerebral blood volume maps in a blinded reader study. AJNR Am J Neuroradiol 2000; 21: 1603-10.
28. Rosen BR, Belliveau JW, Buchbinder BR et al. Contrast agents and cerebral hemodynamics. Magn Reson Med 1991; 19: 285-92.
29. Ostergaard L, Smith DF, Vestergaard-Poulsen P et al. Absolute cerebral blood flow and blood volume measured by magnetic resonance imaging bolus tracking: comparison with positron emission tomography values. J Cereb Blood Flow Metab 1998; 18: 425-32.
30. Liu YJ, Chung HW, Huang IJ et al. A reinvestigation of maximal signal drop in dynamic susceptibility contrast magnetic resonance imaging. J Neuroimaging 2002; 12: 330-8.
31. Cha S, Lu S, Johnson G, Knopp EA. Dynamic susceptibility contrast MR imaging: correlation of signal intensity changes with cerebral blood volume measurements. J Magn Reson Imaging 2000; 11: 114-9.
32. Knopp EA, Cha S, Johnson G et al. Glial neoplasms: dynamic contrast-enhanced T2*-weighted MR imaging. Radiology 1999; 211: 791-8.
33. Ichikawa T, Haradome H, Hachiya J, Nitatori T, Araki T. Characterization of hepatic lesions by perfusion-weighted MR imaging with an echoplanar sequence. AJR Am J Roentgenol 1998; 170: 1029-34.
34. Kuhl CK, Bieling H, Gieseke J et al. Breast neoplasms: T2* susceptibility-contrast, first-pass perfusion MR imaging. Radiology 1997; 202: 87-95.
35. Kvistad KA, Lundgren S, Fjosne HE, Smenes E, Smethurst HB, Haraldseth O. Differentiating benign and malignant breast lesions with T2*-weighted first pass perfusion imaging. Acta Radiol 1999; 40: 45-51.
36. Parker GJ, Baustert I, Tanner SF, Leach MO. Improving image quality and T(1) measurements using saturation recovery turboFLASH with an approximate K-space normalisation filter. Magn Reson Imaging 2000; 18: 157-67.
37. Parker GJ, Suckling J, Tanner SF et al. Probing tumor microvascularity by measurement, analysis and display of contrast agent uptake kinetics. J Magn Reson Imaging 1997; 7: 564-74.
38. Kaiser WA, Zeitler E. MR imaging of the breast: fast imaging sequences with and without Gd-DTPA. Preliminary observations. Radiology 1989; 170 (3 Pt 1): 681-6.
39. van der Woude HJ, Verstraete KL, Hogendoorn PC, Taminiau AH, Hermans J, Bloem JL. Musculoskeletal tumors: does fast dynamic contrast-enhanced subtraction MR imaging contribute to the characterization? Radiology 1998; 208: 821-8.
40. Liu PF, Krestin GP, Huch RA, Gohde SC, Caduff RF, Debatin JF. MRI of the uterus, uterine cervix, and vagina: diagnostic performance of dynamic contrast-enhanced fast multiplanar gradient-echo imaging in comparison with fast spin-echo T2-weighted pulse imaging. Eur Radiol 1998; 8: 1433-40.
41. Barentsz JO, Jager GJ, van Vierzen PB et al. Staging urinary bladder cancer after transurethral biopsy: value of fast dynamic contrast-enhanced MR imaging. Radiology 1996; 201: 185-93.
42. Jager GJ, Ruijter ET, van de Kaa CA et al. Dynamic TurboFLASH subtraction technique for contrast-enhanced MR imaging of the prostate: correlation with histopathologic results. Radiology 1997; 203: 645-52.
43. Huch Boni RA, Boner JA, Lutolf UM, Trinkler F, Pestalozzi DM, Krestin GP. Contrast-enhanced endorectal coil MRI in local staging of prostate carcinoma. J Comput Assist Tomogr 1995; 19: 232-7.
44. Gilles R, Guinebretiere JM, Shapeero LG et al. Assessment of breast cancer recurrence with contrast-enhanced subtraction MR imaging: preliminary results in 26 patients. Radiology 1993; 188: 473-8.
45. Kerslake RW, Fox JN, Carleton PJ et al. Dynamic contrastenhanced and fat suppressed magnetic resonance imaging in suspected recurrent carcinoma of the breast: preliminary experience. Br J Radiol 1994; 67: 1158-68.
46. Mussurakis S, Buckley DL, Bowsley SJ et al. Dynamic contrastenhanced magnetic resonance imaging of the breast combined with pharmacokinetic analysis of gadolinium-DTPA uptake in the diagnosis of local recurrence of early stage breast carcinoma. Invest Radiol 1995; 30: 650-62.
47. Kinkel K, Tardivon AA, Soyer P et al. Dynamic contrastenhanced subtraction versus T2-weighted spin-echo MR imaging in the follow-up of colorectal neoplasm: a prospective study of 41 patients. Radiology 1996; 200: 453-8.
48. Hawnaur JM, Zhu XP, Hutchinson CE. Quantitative dynamic contrast enhanced MRI of recurrent pelvic masses in patients treated for cancer. Br J Radiol 1998; 71: 1136-42.
49. Dao TH, Rahmouni A, Campana F, Laurent M, Asselain B, Fourquet A. Tumor recurrence versus fibrosis in the irradiated breast: differentiation with dynamic gadolinium-enhanced MR imaging. Radiology 1993; 187: 751-5.
50. Heywang-Kobrunner SH, Schlegel A, Beck R et al. Contrastenhanced MRI of the breast after limited surgery and radiation therapy. J Comput Assist Tomogr 1993; 17: 891-900.
51. Blomqvist L, Fransson P, Hindmarsh T. The pelvis after surgery and radio-chemotherapy for rectal cancer studied with Gd-DTPA-enhanced fast dynamic MR imaging. Eur Radiol 1998; 8: 781-7.
52. Leach MO, Boggis CR, Dixon AK et al. Screening with magnetic resonance imaging and mammography of a UK population at high familial risk of breast cancer: a prospective multicentre cohort study (MARIBS). Lancet 2005; 365: 1769-78.
53. Barentsz JO, Berger-Hartog O, Witjes JA et al. Evaluation of chemotherapy in advanced urinary bladder cancer with fast dynamic contrast-enhanced MR imaging. Radiology 1998; 207: 791-7.
54. Reddick WE, Taylor JS, Fletcher BD. Dynamic MR imaging (DEMRI) of microcirculation in bone sarcoma. J Magn Reson Imaging 1999; 10: 277-85.
55. van der Woude HJ, Bloem JL, Verstraete KL, Taminiau AH, Nooy MA, Hogendoorn PC. Osteosarcoma and Ewing's sarcoma after neoadjuvant chemotherapy: value of dynamic MR imaging in detecting viable tumor before surgery. Am J Roentgenol 1995; 165: 593-8.
56. Padhani AR, MacVicar AD, Gapinski CJ et al. Effects of androgen deprivation on prostatic morphology and vascular permeability evaluated with MR imaging. Radiology 2001; 218: 365-74.
57. Knopp MV, Brix G, Junkermann HJ, Sinn HP. MR mammography with pharmacokinetic mapping for monitoring of breast cancer treatment during neoadjuvant therapy. Magn Reson Imaging Clin N Am 1994; 2: 633-58.
58. Devries AF, Griebel J, Kremser C et al. Tumor microcirculation evaluated by dynamic magnetic resonance imaging predicts therapy outcome for primary rectal carcinoma. Cancer Res 2001; 61: 2513-6.
59. de Vries A, Griebel J, Kremser C et al. Monitoring of tumor microcirculation during fractionated radiation therapy in patients with rectal carcinoma: preliminary results and implications for therapy. Radiology 2000; 217: 385-91.
60. Mayr NA, Yuh WT, Arnholt JC et al. Pixel analysis of MR perfusion imaging in predicting radiation therapy outcome in cervical cancer. J Magn Reson Imaging 2000; 12: 1027-33.
61. George ML, Dzik-Jurasz AS, Padhani AR et al. Non-invasive methods of assessing angiogenesis and their value in predicting response to treatment in colorectal cancer. Br J Surg 2001; 88: 1628-36.
62. Morgan B, Thomas AL, Drevs J et al. Dynamic contrastenhanced magnetic resonance imaging as a biomarker for the pharmacological response of PTK787/ZK 222584, an inhibitor of the vascular endothelial growth factor receptor tyrosine kinases, in patients with advanced colorectal cancer and liver metastases: results from two phase I studies. J Clin Oncol 2003; 21: 3955-64.
63. Galbraith SM, Maxwell RJ, Lodge MA et al. Combretastatin A4 phosphate has tumor antivascular activity in rat and man as demonstrated by dynamic magnetic resonance imaging. J Clin Oncol 2003; 21: 2831-42.